HUP0200946A3 - Variants of traf2 which act as an inhibitor of tnf-alpha (tnfalpha) signaling pathway - Google Patents

Variants of traf2 which act as an inhibitor of tnf-alpha (tnfalpha) signaling pathway

Info

Publication number
HUP0200946A3
HUP0200946A3 HU0200946A HUP0200946A HUP0200946A3 HU P0200946 A3 HUP0200946 A3 HU P0200946A3 HU 0200946 A HU0200946 A HU 0200946A HU P0200946 A HUP0200946 A HU P0200946A HU P0200946 A3 HUP0200946 A3 HU P0200946A3
Authority
HU
Hungary
Prior art keywords
traf2
tnfalpha
tnf
variants
inhibitor
Prior art date
Application number
HU0200946A
Other languages
Hungarian (hu)
Original Assignee
Gencell S A Vitry Sur Seine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gencell S A Vitry Sur Seine filed Critical Gencell S A Vitry Sur Seine
Publication of HUP0200946A2 publication Critical patent/HUP0200946A2/en
Publication of HUP0200946A3 publication Critical patent/HUP0200946A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
HU0200946A 1999-04-30 2000-04-06 Variants of traf2 which act as an inhibitor of tnf-alpha (tnfalpha) signaling pathway HUP0200946A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13194099P 1999-04-30 1999-04-30

Publications (2)

Publication Number Publication Date
HUP0200946A2 HUP0200946A2 (en) 2002-07-29
HUP0200946A3 true HUP0200946A3 (en) 2005-06-28

Family

ID=22451697

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200946A HUP0200946A3 (en) 1999-04-30 2000-04-06 Variants of traf2 which act as an inhibitor of tnf-alpha (tnfalpha) signaling pathway

Country Status (10)

Country Link
EP (1) EP1180140A4 (en)
JP (1) JP2002542826A (en)
KR (1) KR20020012194A (en)
CN (1) CN1309830C (en)
AU (2) AU4076800A (en)
CA (1) CA2372803A1 (en)
HU (1) HUP0200946A3 (en)
IL (1) IL146241A0 (en)
MX (1) MXPA01011107A (en)
WO (1) WO2000066737A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003458D0 (en) * 2000-02-16 2000-04-05 Secr Defence Brit Rubber structure & method of making the same
CA2449487A1 (en) * 2001-06-07 2002-12-12 Pu Xia Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
US20050180974A1 (en) * 2003-10-24 2005-08-18 Medtronic, Inc. Extracellular TNF inhibitors for treating CNS disorders
WO2022152856A1 (en) * 2021-01-15 2022-07-21 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Methods and compositions for treating ischaemia in a subject
CN114672550B (en) * 2022-05-05 2023-11-17 青岛大学 Atherosclerosis biomarker and inhibitor and application thereof

Also Published As

Publication number Publication date
CA2372803A1 (en) 2000-11-09
EP1180140A4 (en) 2004-08-25
AU4076800A (en) 2000-11-17
IL146241A0 (en) 2002-07-25
WO2000066737A1 (en) 2000-11-09
JP2002542826A (en) 2002-12-17
AU2005203749A1 (en) 2005-09-15
EP1180140A1 (en) 2002-02-20
KR20020012194A (en) 2002-02-15
CN1309830C (en) 2007-04-11
HUP0200946A2 (en) 2002-07-29
CN1353754A (en) 2002-06-12
MXPA01011107A (en) 2002-08-09
WO2000066737A9 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
EP1406875A4 (en) N-heterocyclic inhibitors of tnf-alpha expression
AU8419201A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
PL370909A1 (en) Cis-imidazolines as mdm2 inhibitors
AU3408801A (en) Tnf-alpha inhibitors
SI1458377T1 (en) Tegaserod pharmaceutical compositions
GB9927315D0 (en) Inhibitor compositions
GB0316313D0 (en) Methods for specifically inhibiting histone deacetylase-4
EP1567008A4 (en) Protection of stem cells from cytotoxic agents by modulation of beta-catenin signaling pathways
GB9930659D0 (en) Inhibitors of complement activation
GB9923866D0 (en) Correlation of signalling messages
AU5969101A (en) Modulators of tnf-alpha signaling
GB0127745D0 (en) Protection of double circuit power lines
GB0016524D0 (en) Protection of incendive circuits
IL136156A0 (en) Sequences of trail variants
HUP0102363A3 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
HUP0200946A3 (en) Variants of traf2 which act as an inhibitor of tnf-alpha (tnfalpha) signaling pathway
AU2003249428A8 (en) Video circuit
EP1221963A4 (en) Methods of inhibiting osteoclastogenesis
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
EP1409463A4 (en) N-heterocyclic inhibitors of tnf-alpha expression
AU2003299137A8 (en) Inhibition of metallo-beta-lactamase
GB0113076D0 (en) System for automatic provision of property details
AU2003271988A8 (en) Modulation of tgfbeta-like signalling pathways
TW539382U (en) Waterproof structure of distributor connector
AU2003249530A8 (en) Video circuit

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees